Keywords included macular degeneration with preference or utility or names of all possible techniques/tools used to derive utility or other synonyms. Original articles reporting health state utilities of patients with AMD were included. All articles were reviewed and extracted independently by two investigators for study design, population and outcomes. Meta-analyses were performed using DerSimonian and Laird method under a random-effects model. RESULTS: Out of 1887 studies identifi ed, 24 studies met inclusion criteria. Twenty-one studies obtained utility directly from patients, while the others inquired ophthalmologists or community members to estimate utility. Standard Gamble (SG) and time-trade off (TTO) were the most commonly techniques used in these studies (11 studies used TTO, while 5 studies used SG). Based on a meta-analysis of three studies which obtained utility from 510 patients and provided suffi cient data for calculation, the utility values with 95% confi dence intervals for visual acuity of 20/20-20/25, 20/30-20/50, 20/60-20/100, 20/200-20/400 and <20/400 were 0.91 (0.88-0.94), 0.81 (0.78-0.84), 0.68 (0.58-0.77), 0.62 (0.55-0.68), and 0.46 (0.33-0.59) respectively. CONCLUSIONS: Our fi ndings provided the pooled estimates of utilities for AMD patients for all visual acuity levels. It was found that the better visual acuity, the higher utility value. Researchers may use our pooled utilities as input parameters in their cost-effectiveness modeling studies. Psoriasis has a major impact on patients' quality of life, as commonly measured by the Dermatology Life Quality Index (DLQI). This study has two objectives: 1) to measure health-related utilities for patients with psoriasis and to measure the willingness-to-pay (WTP) for a cure for psoriasis, and 2) to examine how these different measures of utilities and WTP were related to DLQI. METHODS: Face-toface patient interviews were carried out with 364 patients with psoriasis during August 2009 and February 2010 at dermatology outpatient clinics in fi ve hospitals located in northern, central and southern Taiwan. Utilities were elicited using time trade-off (TTO), visual analogue scale (VAS) and EQ-5D. The EQ-5D was scored based on the standard scoring formula. The WTP for a cure of psoriasis was elicited by double bounded binary-choice questions followed by a bidding game question. RESULTS: Mean age was 44.5 years, mean history of disease was 11.2 years, and 77% of patients were male. The mean health utility was 0.87 (EQ-5D), 0.72 (VAS) and 0.75 (TTO). The WTP per month was between NT$7770.72 and NT$9411.50. Scores of EQ-5D and VAS were signifi cantly negatively correlated to all of the dimensions of DLQI. The correlation of the dichotomous WTP with DLQI was also strong and in the expected direction. TTO was also signifi cantly correlated with DLQI, but the relation was the weakest. CONCLUSIONS: EQ-5D, VAS and WTP are consistent measures with DLQI in assessing the well-being of patients with psoriasis in Taiwan.
PSS11 MEDICATION CHOICE AND ASSOCIATED HEALTH-CARE OUTCOMES AND COSTS FOR PATIENTS WITH PSORIASIS IN THE UNITED STATES
Lin HC 1 , Balkrishnan R 1 , Lucas PTR 2 , Feldman SR 3 1 University of Michigan, Ann Arbor, MI, USA; 2 Universidade de Lisboa, Lisboa, Portugal; 3 Wake Forest University, Winston-Salem, NC, USA OBJECTIVES: The impact of choice of pharmacotherapy for psoriasis on costs and patient outcomes in large nationally representative data in the United States needs further examination. This study examined the impacts of patient demographics and medication choices on patient's health status and associated medication costs in the United States. METHODS: A retrospective cross-sectional study was conducted using the 2007 Medical Expenditure Panel Survey (MEPS) database. Information on patient demographics, health status, medication utilization, and medication costs were obtained from the database representing 605,089 patients with psoriasis. Weighted multiple linear regressions were used to examine the impacts of patient demographics and medication choices on patient's health status and associated medication costs. RESULTS: Weighted multiple linear regression analyses indicated that the use of topical corticosteroids yielded 23.0% lower annual medication costs (compared to nonusers in logarithm format; P = 0.00), whereas the use of biological/systemic agents yielded 41.8% higher annual medication costs (compared to nonusers in logarithm format; P = 0.00). The study population using topical corticosteroids had 35.0% improvement in SF-12 PCS scores (compared to nonusers; P = 0.00), whereas patients using biological/systemic agents had 8.2% improvement in SF-12 PCS scores (compared to nonusers; P = 0.00. ) The use of biological agents was elevated compared to previous studies. CONCLUSIONS: We observed an association with medication choice for psoriasis treatment on associated patient health status and medication spending in the United States. The retrospective nature of the study precludes assessment of causality, but encouraging use of topical treatments may be an effective means to reduce psoriasis management costs.
PSS12 PSYCHOMETRIC EVALUATION OF MYOPIA-SPECIFIC INSTRUMENTS USED TO ASSESS HEALTH-RELATED QUALITY OF LIFE FOR PATIENTS RECEIVING LASIK SURGERY
Huang MY University of Georgia, Athens, GA, USA OBJECTIVES: The objective of this study is to identify an existing instrument which could measure the health related quality of life of myopia patients receiving refractive surgery such as LASIK for group-level and individual-level decision-making. METHODS: Seven instruments were identifi ed through a comprehensive literature search. Based on the criteria defi ned by Scientifi c Advisory committee of the Medical Outcome Trust (2002), selected instruments were evaluated using 12 criteria related to conceptual model, reliability (internal consistency and test-retest), validity(content validity and construct validity), responsiveness(cross-sectional and longitudinal), interpretability(availability of norms and quality of norms), burden(respondent and administrator), and depth. RESULTS: For the seven identifi ed instruments, two were excluded because language criteria and one was excluded because it measured satisfaction, not HRQOL. The remaining four instruments included National Eye Institute Refractive Error Quality of Life (NEI-RQL), Refractive Status and Vision Profi le (RSVP), Quality of Life Impact of Refractive Correction (QIRC), Quality-of-life Scale for Myopia (QOLM). For 12 individual decision-making criteria, NEI-RQL, RSVP, QIRC and QOLM met 7, 7, 6, 5 criteria, respectively. For 12 group-level decisionmaking criteria, NEI-RQL, RSVP, QIRC and QOLM met 9, 7, 8, 7 criteria, respectively. CONCLUSIONS: Existing instruments do not fully meet the evaluation criteria. Most instruments lacked information or had problems with reliability (individual-level decision-making), longitudinal responsiveness, administrator burden, and depth. This study results showed that NEI-RQL met the most of the criteria. For an international study, the NEI-RQL-42 had to be translated and linguistically validated in Simplifi ed Chinese for China and Hindi for India. METHODS: A standardized linguistic validation methodology was conducted by specialists for each target country: 1) concept defi nition; 2) dual forward translations by independent native-speaking linguists; 3) reconcili-ation of the forward translations; 4) back translation into English by a native speaking linguist; 5) resolution of the back translation; 6) international harmonization; 7) clinician (Ophthalmologist) review; 8) cognitive debriefi ng comprehension interviews on fi ve Mandarin/Simplifi ed Chinese and fi ve Hindi native-speaking patients who are either pre-or post-cataract surgery; and 9) fi nal proofreading. RESULTS: The main challenge on the conceptual level was the English original made extensive use of driving scenarios during the day and night in the US English source instrument to elicit responses. For Hindi and Simplifi ed Chinese, driving scenarios were supplemented with walking and cycling, which were more relevant in the local context without compromising the conceptual intent of the source instrument. On the linguistic level, translating some of the frequency terms required discussion with the developer to identify a solution, as the gradation between the surrounding English response options was diffi cult to exactly match on a conceptual level in the target language due to linguistic limitations. CONCLUSIONS: According to the rigorous methodology used, with some minor adjustments, the Mandarin and Hindi versions of the NEI-RQl-42 were qualitatively conceptually equivalent and culturally relevant. The Simplifi ed Chinese and Hindi versions were successfully linguistically validated to measurement of the impact of refractive error on patients' day-to-day lives and facilitate the comparison and pooling of data.
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PSS14 WHAT COST OF HLA-B*5801 GENOTYPING WOULD BE COST-EFECTIVE FOR THE PREVENTION OF ALLOPURINOL-INDUCED STEVENS JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS IN THAILAND: ANALYSES USING A DECISION-ANALYTIC MODEL
Center of Pharmaceutical Outcome Research, Naresuan University, Muang, Phitsanulok, Thailand; 2 Naresuan University, Muang, Phitsanulok, Thailand, 3 Department of Pharmacology, Faculty of Medicine, Khon Kaen, Thailand OBJECTIVES: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), caused by allopurinol therapy, are strongly associated with the human leukocyte antigen (HLA), HLA-B*5801. It was unclear at what price the genetic testing would be a cost-effective strategy compared to no testing. This study aims to determine the range of genotyping cost that would be cost-effective from health-care provider perspective. METHODS: A decision analytic model was used to estimate the cost-effectiveness of HLA-B*5801 genotyping compared to no testing. The incidence of SJS/TEN was estimated based on case reports from Health Product Vigilance Center of Thailand in year 2009. The prevalence of HLA-B*5801 was obtained from Thai population reported in dbMHC database, while the association of gene and SJS/TEN was based on a meta-analysis. Cost of SJS/TEN management and case-fatality rate were derived from National Inpatient Governmental Hospital Database in year 2007. We used PG5801 DNA detection kit as a genotyping tool with 100% sensitivity and specifi city. We varied genotyping costs and selected values that would make the costeffectiveness values being 100,000 or 300,000 THB/life-year gained. One-way sensitivity analysis was undertaken to identify infl uential parameters. RESULTS: The estimated life-years (LY) were 21.9999 and 21.9964 for testing and no testing groups, respectively. Setting the genotyping cost as 393 and 1085 THB resulted in a potentially cost-effectiveness range of 100,000 and 300,000 THB/LY, respectively. The most infl uential parameters were the cost of genotyping and SJS/TEN management. CONCLUSIONS: Pharmacogenetic testing for HLA-B*5801 appears to be potentially cost-effective if the testing cost falls in the range of 393 and 1085 THB. It was important to note that this analysis has not taken into account sequelaes associated with SJS/TEN and has not performed based on the societal perspective yet. Policymakers should consider our fi ndings for guiding health policy during decision-making process. Novo Nordisk A/S, Soeborg, Denmark; 2 IMS Health, Redwood City, CA, USA; 3 IMS Health Inc, Falls Church, VA, USA OBJECTIVES: A US hospital-based economic model was developed to quantify the potential cost savings associated with use of an improved non-immunogenic bypassing agent with faster bleeding resolution, sustained control and a reduced need for retreatment in order to estimates the inpatient costs for on-demand treatment of bleeds of hemophilia patients with inhibitors. METHODS: An Excel-based model patterned the inpatient care associated with use of currently available bypassing agents: plasmaderived activated prothrombin complex concentrate (pd-aPCC) and recombinant Factor VIIa (rFVIIa). We used the model to simulate the potential impact of faster bleeding resolution associated with an improved bypass agent by examining a realistic range of theoretical improvements to the rFVIIa profi le. The model was parameterized with treatment-specifi c average resource use, service and pharmacy costs, and source admission estimates based on a retrospective analysis of the Premier Perspective™ Database, including 1218 inpatient stays with an ICD-9 diagnosis of hemophilia A that were identifi ed from [2003] [2004] [2005] [2006] [2007] [2008] . All costs are reported in 2008 USD. RESULTS: In the baseline analysis, the average per-patient costs associated with the inpatient treatment of hemophilia with inhibitors were slightly lower with rFVIIa as compared with pd-aPCC ($78,086 vs. $78,141). The observed cost difference was attributable to an observed difference in the percentage of inpatient stays where the patient was admitted through the ER associated (rFVIIa: 54%; pd-aPCC: 80%). Exploratory sensitivity analyses showed that a potentially faster-acting non-immunogenic treatment (e.g., 10% reduction in length of stay per patient admittance and a 10% reduction in average duration of bypass agent therapy per patient admittance) could impart appreciable incremental cost savings of $7867 (10.1%) compared with pd-aPCC treatment. CONCLUSIONS: Our analysis showed that the availability of more effective bypassing agents with faster bleed resolution may have the potential to confer signifi cant inpatient cost savings through reductions in length of stay and duration of bypass agent treatment. To examine utilization of health-care services and factor concentrate among persons with hemophilia A receiving care at US Hemophilia Treatment Centers (HTCs). METHODS: Hemophilia Utilization Group Study (HUGS-Va) is a prospective multicenter study evaluating burden of illness and cost of care in persons with hemophilia A in the United States. Patients or parents of patients < 18 from six HTCs completed a standardized interview, including demographics, health insurance coverage, barriers to care and treatment pattern. One-year clinical data and two-year dispensing records were abstracted for health care and factor utilization. Annual factor use and costs were calculated as the average of two-year data. Generalized linear model with Poisson distribution was used to assess the association between factor replacement and emergency room visits after adjusting for covariates. RESULTS: Of 329 participants (50% adults), 68% had severe hemophilia. Ninety-one percent reported using health services at least once during the year: 65% had a HTC comprehensive evaluation, 33% visited a clinician, 21% had physical therapy, 28% visited the emergency room, and 14% were hospitalized. Emergency room visits per personyear were 58% lower among prophylaxis users (vs.episodic) after adjusting for age, employment, and insurance coverage (RR = 0.42, P = 0.002). Patients without inhibitors and severe disease had signifi cantly more factor dispensed (4236 u/kg/yr), compared to those with moderate (1089 u/kg/yr) or mild (582 u/kg/yr) disease (P < 0.0001). The average factor cost was $165,188 (median: $104,170) per patient-year in persons without inhibitors and $700,272 (median: $197,621) in patients with inhibitors. CONCLUSIONS: Patients access an array of comprehensive health services provided by HTCs. Prophylactic infusion of factor may be associated with decreased health-care utilization compared to episodic treatment.
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PSY3 HEALTH-CARE UTILIZATION AND COST IN PERSONS WITH FACTOR VIII DEFICIENCY: RESULTS OF THE HUGS VA STUDY
PSY4 COMPARATIVE COST-EFFECTIVENESS ANALYSES OF IRON CHELATING THERAPIES IN TRANSFUSION-DEPENDENT THALASSAEMIA POPULATION IN THAILAND
Luangasanatip N 1 , Chaiyakunapruk N 2 , Upakdee N 2 , Wong P 3 1 City University, London, UK; 2 Naresuan University, Muang, Phitsanulok, Thailand; 3 Faculty of Medicine, Naresuan University, Muang, Phitsanulok, Thailand OBJECTIVES: Thalassaemia is one of the major public health problems in Thailand. Using appropriate iron chelating agents could prevent thalassemia-related complications which are costly to the health-care system. This study aims to evaluate the cost-effectiveness of Deferoxamine (DFO), Deferiprone (DFP), and Desferasirox (DFX) in transfusion-dependent thalassaemia patients from the societal perspective. METHODS: A Markov model was used to project the life time costs and outcomes represented as quality-adjusted life-years (QALYs). Clinical effi cacy and safety of all therapeutic options were obtained from a systematic review and clinical trials. Transition probabilities were derived from literatures while costs were obtained from Thai Drug and Medical Supply Information Center, Diagnostic Related Group (DRG) and other Thai literatures. Discounting rate of 3% was used. Incremental cost-effectiveness ratios were presented as values of year 2009. A series of sensitivity analysis and cost effectiveness analysis curve (CEAC) were performed. RESULTS: Compared with DFO, using DFP is dominant with cost-savings of US$ 91,107 without QALYs gained. Comparing DFX with DFO, the incremental cost was US$ 129,565 and incremental QALY was 5.35 with an incremental cost-effectiveness ratio of US$ 22,463. When compared to DFP, an incremental cost-effectiveness ratio of DFX was US$ 38,258 per QALY. Cost effectiveness analysis curve (CEAC) showed that the probability of DFX being cost-effective was 0% when compared with either DFO or DFP, based on the cost-effectiveness cut-off value of US$ 2,902 per QALY. When compared to DFP, DFX is cost-effective only if DFX cost was lowered from US$ 14.6 to US$ 4 per tablet. CONCLUSIONS: Our fi ndings suggest that using DFP is cost-saving when compared with the conventional therapy, while using DFX is not cost-effective compared with both DFO and DFP. Policymakers and clinicians may consider using such information for aiding policy decision-making process in Thailand. To evaluate the cost-effectiveness of deferasirox (DFS) versus deferoxamine (DFO) in patients with β-thalassaemia major from a Hong Kong (HK) public health-care system perspective. METHODS: A Markov model previously developed for the United States was adapted to examine the potential cost-effectiveness with DFS versus DFO based on lifetime costs and QALYs gained in transfusion-dependent β-thalassaemia patients in HK. Patients were assumed to have initiated chelation therapy at 3 years of age and have received prescribed dosages of DFS or DFO that have been shown to be similarly effective in β-thalassaemia patients. Probabilities of complications of iron-overload and death due to poor compliance with chelation therapy were estimated using data from recently published studies. Iron chelator dosages, costs of administration, and iron overload-related complications were collected from hospital medical records (from January 2004 to December 2009) of transfusion-dependent β-thalassaemia patients. Health-state utility values were based on a recent study of patients' preferences for oral versus infusional therapy and published literature. A 5% annual discount rate was used. RESULTS: Compared with DFO, DFS yielded an additional 3.15 QALYs gained per patient at an additional lifetime expected cost of $156,881 USD ($1.22M HKD) per patient; the cost per QALY gained was $US49,761 ($388K HKD). The results were sensitive to the estimated infusional administration costs for DFO, the rates of compliance associated with oral versus infusional therapy, estimates of the daily dose of DFS, and unit costs of each chelator. CONCLUSIONS: Based on the WHO recommended thresholds that any incremental cost-effectivess ratio lower than three-times the GDP per capita can be considered as cost-effective (GDP of HK in 2009 was $US 29,902), results of this study suggest that DFS is probably a cost-effective iron chelator for patients with transfusion-dependent β-thalassaemia.
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COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG-AN INITIAL ANALYSIS
